Rituximab: profile and news
Pixantrone Produces High Rate of Complete Tumor Disappearance in ... 16 May 2006
SEATTLE, WA -- May 16, 2006 -- Preliminary results of a phase 1/2 study of pixantrone combined with fludarabine, dexamethasone, and rituximab for treatment of ... - DG News
The efficacy and safety of Rituximab in patients with active ... May 3, 2006
...cell. Rituximab, a biologic agent that selectively depletes B cells, has been successfully used to treat non-Hodgkin's lymphoma. ... - News-Medical.net,
The promise of a B-cell biologic therapy for rheumatoid arthritis Apr 30, 2006
May 1 (EurekAlert): Rituximab achieves remission in patients resistant to conventional DMARDs, regardless of dosage and independent of steroids, finds ... - Hindu,
'Biologic' Drug Fights Rheumatoid Arthritis Apr 28, 2006
...report. The drug, rituximab (brand name Rituxan), has already proven safe and effective in treating non-Hodgkins lymphomas. But ... - Forbes
Point Therapeutics Reports First Quarter 2006 Financial Results ... May 9, 2006
...from a $600,000 Orphan Products Development grant which is funding a portion of Point's current Phase 2 study combining talabostat with rituximab in advanced ... - Genetic Engineering News,
Genitope Corporation to Present Phase 2 Clinical Trial Data at ... May 2, 2006
Nasdaq: GTOP - News) today announced that data from its ongoing Phase 2 clinical trial evaluating MyVax® personalized immunotherapy following rituximab as a ... - Yahoo! News (press release)
Millennium and Johnson & Johnson Pharmaceutical Research and ... Apr 18, 2006
Research & Development, LLC (J&JPRD) today announced the initiation of a Phase III clinical trial of VELCADE in combination with rituximab in patients with ... - Yahoo! News (press release)
Genitope Corporation to Present Phase 2 Clinical Trial Data at ... May 2, 2006
NASDAQ: GTOP) today announced that data from its ongoing Phase 2 clinical trial evaluating MyVax(R) personalized immunotherapy following rituximab as a ... - PR Newswire (press release),
IU targeting Type I diabetes May 2, 2006
Q: How do you hope to stop the B cells? A: We're using a drug, rituximab, used to treat lymphoma, or cancer of the white blood cells. ... - Indianapolis Star,
Genta Incorporated Announces First Quarter 2006 Financial Results ... May 9, 2006
The Company has also submitted to the FDA a Special Protocol Assessment (SPA) for a Phase 4 study of rituximab (Rituxan(R); Genentech Idec) and fludarabine ... - International News Service,
ImmunoMedics/UCB: Looking to Lupus May 11, 2006
However, epratuzumab looks set to face fierce competition from products such as Biogen Idec/Genentech's rituximab and Chugai's IL-6 modulator tocilizumab ... - International News Service,
Genentech Announces Vice President Appointments in Commercial ... May 11, 2006
Genentech's BioOncology marketed products include Avastin(R) (bevacizumab), Herceptin(R) (Trastuzumab), Rituxan(R) (Rituximab), and Tarceva(R) (erlotinib). ... - Finanzen.net,
Point Therapeutics to Present at Rodman & Renshaw 3rd Annual ... May 9, 2006
2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced ... - International News Service,
Rheumatoid Arthritis Clinical Trials Investigating Rituxan: Are ... May 11, 2006
Three rheumatoid arthritis clinical trials investigating Rituxan (rituximab) are taking place at more than 200 US medical facilities. ... - About - News & Issues,
Rituxan® Improves Outcomes of Young Patients with Good-Prognosis ... May 1, 2006
Researchers affiliated with the MabThera International Trial (MInT) Group have reported that Rituxan (rituximab) added to six cycles of CHOP-21 ... - Cancer Consultants (press release),
Velcade enters end-stage lymphoma trial Apr 19, 2006
The trial will evaluate the drug in combination with rituximab in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin's lymphoma ... - Pharmaceutical Business Review
Immunomedics and UCB Announce Worldwide Development Collaboration ... May 9, 2006
Three studies have been completed which indicate a potential value in combining epratuzumab with rituximab, an approved CD20 monoclonal antibody. ... - Yahoo! News (press release)
Genitope To Present Results Of Phase 2 Study Of MyVax On June 4 At ... May 2, 2006
...charts | news | PowerRating) announced that data from its ongoing Phase 2 clinical trial evaluating MyVax personalized immunotherapy following rituximab as a ... - Trading Markets,
Millennium, Johnson & Johnson Start Phase III Clinical Trial With ... Apr 18, 2006
Johnson Pharmaceutical Research & Development, LLC revealed the commencement of a Phase III clinical trial of VELCADE in combination with rituximab in patients ... - Trading Markets,
Rituxan Safe and Effective In Rheumatoid Arthritis Apr 28, 2006
LEEDS, England, April 28 — Rituxan (rituximab) is effective and well-tolerated in patients with active rheumatoid arthritis, according to researchers here. ... - MedPage Today,
Dose-Dense R-CHOP-14 Can Be Safely Administered to NHL Patients ... Apr 25, 2006
...effective supportive care for patients with diffuse large B-cell lymphoma (DLBCL) receiving dose-dense R-CHOP-14 (rituximab-cyclophosphamide, doxorubicin ... - Cancer Consultants (press release),
Millennium Achieves First Quarter 2006 Non-GAAP Profitability and ... Apr 27, 2006
Research & Development, LLC (J&JPRD) initiated a two-arm, randomized, open-label, multi-center, Phase III study of VELCADE and rituximab in patients with ... - Yahoo! News (press release)
SuperGen Reports 2006 First Quarter Financial Results Apr 20, 2006
March 2006: The Company announced that an article entitled, "Pentostatin, Cyclophosphamide, and Rituximab is an Active, Well-Tolerated Regimen for Patients ... - Yahoo! News (press release)
ZymoGenetics Reports First Quarter 2006 Financial Results May 4, 2006
The Phase 1 trial of the combination of IL-21 and rituximab in patients with non-Hodgkin's lymphoma is expected to commence within the next several months. ... - PR Newswire (press release),
International Orphan Drug Approvals: 1D09C3 and Nexavar Apr 21, 2006
...to the major histocompatability complex class 2 molecule, which differs from that targeted by currently marketed products such as rituximab (Rituxan, made by ... - Medscape (subscription)
Biogen Idec buys cancer drug firm Conforma May 4, 2006
...and Phase I testing, so the acquisition is aimed more at boosting its medium- to long-term cancer portfolio, currently headed by Rituxan (rituximab) for non ... - Pharma Times (subscription),
Millennium Begins Phase III Trial Of Velcade Apr 18, 2006
Millennium Pharmaceuticals Inc. (MLNM) started a Phase III trial of Velcade with rituximab to study progression-free survival in patients with relapsed or ... - Therapeutics Daily (subscription) (press release),
Hospitals may have to close to pay for new drugs, says Hewitt Apr 22, 2006
...disease. There are similar problems for drugs that treat non-Hodgkin's lymphoma, called Rituximab, or Alimta, which treats lung cancer. ... - Independent,
Cancer drug shame Apr 22, 2006
Decision expected in July. MABTHERA (rituximab): Considered the breakthrough drug in this class — the first therapeutic antibody approved for cancer. ... - The Age,
Biogen Idec Reports First Quarter 2006 Results Apr 26, 2006
...prior year $588 million, an increase of 4%, driven primarily by RITUXAN(R) (rituximab) revenues from the unconsolidated joint business arrangement up 14% to ... - Genetic Engineering News,
Algeta publishes results of new thorium-227 mAb conjugate Apr 20, 2006
TH-1 Therapeutic Antibody Enhancement technology, it has been shown that in vivo a Thorium-227 conjugate of the chimeric mAb rituximab retains immunoreactivity ... - Therapeutics Daily (subscription) (press release),
Angel Christal FFundraiser Slated April 29 at 4-H Community Center Apr 24, 2006
In addition to the chemo treatment, Angel is taking part in a clinical trial option where she is taking the medicine Rituximab. ... - Bluffton News Banner,
Business notebook Apr 19, 2006
...of Cambridge started a phase 3 trial of Velcade with rituximab to study progression-free survival in patients with relapsed or refractory follicular lymphoma ... - Boston Globe,
Survival Improving for Patients with Stage IV Follicular Lymphoma Apr 17, 2006
...salvage therapies with autologous stem cell transplants and the introduction of monoclonal antibody therapy with Rituxan® (rituximab), Bexxar® (iodine 131 ... - Cancer Consultants (press release),
Dose-Dense Therapy for NHL Safely Administered with Support of ... Apr 18, 2006
...with Neulasta® (pegfilgrastim) allowed for the safe administration of the dose-dense treatment regimen R-CHOP-14 (rituximab-cyclophosphamide, doxorubicin ... - Cancer Consultants (press release),
Dynavax's Early Stage Pipeline Advancing With $50M Vehicle Apr 20, 2006
The company has an ongoing Phase IIa trial of its drug candidate in combination with Rituxan (rituximab) in patients with non-Hodgkin's lymphoma. ... - BioWorld Online (subscription),
